Explore more publications!

Health & Wellness Today New York: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.

Press releases published on September 29, 2025

Plant Parenting Emerges as 2025’s Wellness Trend: Stress Relief, Cleaner Air, and Focus Gains
Wellbridge Highlights Need for Specialized Addiction Treatment for First Responders
Wellbridge Drug & Alcohol Rehab Highlights the Importance of Aftercare in Sustaining Recovery
Wellbridge Long Island Rehab Emphasizes Specialized Care for Healthcare Professionals
Digitas Health Names Widerson Souza and Thiago Fernandes Deputy Chief Creative Officers
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Artelo Biosciences Announces Proposed Underwritten Public Offering
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
NANOBIOTIX annonce de nouveaux résultats de Phase 1 qui continuent de confirmer le potentiel de JNJ-1900 (NBTXR3), avec un anti-PD-1, en tant que potentielle nouvelle option thérapeutique de première ou deuxième ligne ou plus dans le CETEC R/M naïf ou …
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements
INVO Fertility to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
MAIA Biotechnology Announces $2.25 Million Private Placement
Precision Optics Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions